Assessing the Safety of Dapivirine Gel and Film Formulations

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2013 by International Partnership for Microbicides, Inc.
Sponsor:
Information provided by (Responsible Party):
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
NCT01548560
First received: March 1, 2012
Last updated: March 6, 2013
Last verified: March 2013

March 1, 2012
March 6, 2013
August 2012
February 2014   (final data collection date for primary outcome measure)
Number of Grade 2 or higher Adverse Events [ Time Frame: 5-11 weeks ] [ Designated as safety issue: Yes ]
The safety/toxicity endpoint is clinical or laboratory evidence of a Grade 2 or higher Adverse Event as defined by the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 and the Female Genital Grading Table for Use in Microbicide Studies which is judged to be related to study product.
Same as current
Complete list of historical versions of study NCT01548560 on ClinicalTrials.gov Archive Site
  • Changes in vaginal flora and vaginal pH [ Time Frame: 5-11 weeks ] [ Designated as safety issue: Yes ]
  • Systemic and local absorption levels of dapivirine [ Time Frame: 5-11 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Assessing the Safety of Dapivirine Gel and Film Formulations
Not Provided

This is a study to determine the safety of dapivirine gel and dapvirine film for healthy, HIV-uninfected women aged 18-45 years using the product for 7 daily doses.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
HIV Infections
  • Drug: Dapivirine Vaginal Film
    Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
  • Drug: Dapivirine Vaginal Gel
    Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
  • Experimental: Dapivirine Vaginal Gel
    Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
    Interventions:
    • Drug: Dapivirine Vaginal Film
    • Drug: Dapivirine Vaginal Gel
  • Placebo Comparator: Placebo Gel
    Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
    Intervention: Drug: Dapivirine Vaginal Gel
  • Experimental: Dapvirine Vaginal Film
    Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
    Interventions:
    • Drug: Dapivirine Vaginal Film
    • Drug: Dapivirine Vaginal Gel
  • Placebo Comparator: Vaginal Film
    Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
    Intervention: Drug: Dapivirine Vaginal Film
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
February 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 18 through 45 years (inclusive) at screening
  • Able and willing to provide written informed consent to be screened for and to take part in the study.
  • Able and willing to provide adequate locator information
  • HIV-uninfected based on testing performed by study staff at screening (per algorithm in Appendices I)
  • Per participant report, using an effective method of contraception at enrollment; hormonal method (except vaginal ring) used continuously for the past 30 days; intrauterine device (IUD inserted at least 30 days prior to enrollment); female sterilization; abstinent from sexual activity with male partner for the past 30 days; or sexual activity with vasectomized partner; and willingness to use effective method of contraception until the completion of final scheduled study visit if enrolled (approximately 35 days after enrollment)
  • In general good health as determined by the site clinician
  • For participants older than 21, a pap result in the 12 calendar months prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009) or satisfactory evaluation with no treatment required of non-Grade 0 Pap result per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines or per local standard of care, in the 12 calendar months prior to the Enrollment

Note: For participants aged 18-21, a Grade-0 or adequately evaluated abnormal Pap smear is not required as the American Society for Colposcopy and Cervical Pathology recommends initiating screening at age 21.

  • Agree to be sexually abstinent from Visit 1 until the completion of Visit 3
  • Agree to use study condoms between Visits 3 and 4 (if heterosexually active)
  • Agree to abstain from any other intravaginal product or penetration (including sex toys, excluding tampons) until Visit 3
  • Willingness to undergo all study-related assessments and follow all study-related procedures
  • At screening and enrollment, agrees not to participate in other research studies involving drugs, medical devices, or vaginal products while enrolled in this trial

Exclusion Criteria:

  • Menopause (as defined as amenorrhea for one year or more without an alternative etiology)
  • Hysterectomy
  • Participant report of any of the following:

    • Known adverse reaction to any of the study products (ever)
    • Known adverse reaction to latex (ever)
    • Non- therapeutic injection drug use in the 12 months prior to Screening
    • Surgical procedure involving the pelvis in the 90 days prior to enrollment (includes dilation and curettage or evacuation, and cryosurgery; does not include cervical biopsy for evaluation of an abnormal pap smear)
    • Participation in a drug, spermicide and/or microbicide study in the 30 days prior to enrollment or anticipated participation in an investigational drug study in the next 8 weeks
    • Pregnancy within 90 days of enrollment
    • Currently lactating
    • Use of a diaphragm, NuvaRing®, or spermicide for contraception
    • Internal vaginal use of any device or product (except tampons) in the 7 days prior to enrollment
  • Urogenital infection or suspected infection within 14 days of enrollment including: symptomatic candidiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis; or cervical infection, including N. gonorrhea, C. trachomatis, or mucopurulent cervicitis; syphilis; HSV lesions, or other sores (Note: seropositive HSV without active lesions will not be excluded); acute pelvic inflammatory disease; urinary tract infection; recent exposure to a partner with GC, CT, Trichomonas, syphilis, or NGU
  • Antibiotic or antifungal therapy (vaginal or systemic) within 7 days of enrollment
  • As determined by the PI, has any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease
  • Menses or other vaginal bleeding at the time of the Enrollment visit
  • Has any of the following laboratory abnormalities per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 December 2004:

    • Grade 1 or higher AST or ALT
    • Grade 1 or higher creatinine
    • Grade 2 or higher hemoglobin
    • Grade 1 or higher platelets (Note: otherwise eligible participants with an exclusionary test may be re-tested during the screening process).
  • Any condition that, in the opinion of the Investigator, would preclude provision of consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Female
18 Years to 45 Years
Yes
Contact: Katherine Bunge, MD MPH 412-641-6435
Contact: Annalene Nel 301-608-2221 anel@ipmglobal.org
United States
 
NCT01548560
FAME 02
Not Provided
International Partnership for Microbicides, Inc.
International Partnership for Microbicides, Inc.
Not Provided
Study Chair: Katherine Bunge, MD MPH Magee Womens Hospital, UPitt
International Partnership for Microbicides, Inc.
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP